SAGE Sage Therapeutics
- 13.600
- +0.495+3.78%
Sage Therapeutics News
Sage Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on Sage Therapeutics, Lowers Price Target to $28
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Gilead Sciences (GILD) and SAGE Therapeutics (SAGE)
Goldman Sachs: Maintaining the Sage Therapeutics (SAGE.US) rating, adjusted from neutral to neutral, and adjusted the target price from $28.00 to $19.00.
Sage Therapeutics Analyst Ratings
SAGE Therapeutics: Hold Rating Amidst Zurzuvae Success and Dalzanemdor Setbacks
Balancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial Reassessment
SAGE Therapeutics (SAGE) Receives a Hold From RBC Capital
Needham: Reiterates that Sage Therapeutics (SAGE.US) holds the rating.
Sage Therapeutics Analyst Ratings
SAGE Therapeutics' Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold Rating
Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained
Hold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline Uncertainty
Analysts Offer Insights on Healthcare Companies: Lisata Therapeutics (LSTA) and SAGE Therapeutics (SAGE)
Needham: Reiterates that Sage Therapeutics (SAGE.US) holds the rating.
SAGE Therapeutics: Hold Rating Amidst Mixed Financial and Market Signals
Sage Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Accolade (ACCD) and Intuitive Surgical (ISRG)
TD Cowen: Maintaining the Sage Therapeutics (SAGE.US) rating, adjusted from buy to buy rating, and adjusted the target price from $30.00 to $16.00.
TD Cowen Maintains Buy on Sage Therapeutics, Lowers Price Target to $16
Analysis
Price Target
No Data
